Does TYK2/JAK1 Show Potential in Inflammatory Diseases? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

  • By

  • Andrea Surnit

  • July 6, 2026

  • 3 min

Share

Clinical Scorecard: Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

At a Glance

CategoryDetail
ConditionInflammatory Diseases
Key MechanismsInhibition of TYK2 and JAK1 pathways
Target PopulationHealthy participants
Care SettingPhase 1 clinical trial

Key Highlights

  • SDC-1801 was well tolerated with mild to moderate adverse events.
  • Evidence of pharmacologic activity with reductions in IP-10 and high-sensitivity C-reactive protein.
  • Peak plasma concentrations observed 3 to 5 hours post-administration.
  • Food intake modestly increased drug exposure.
  • Limited renal elimination with less than 4% recovered unchanged in urine.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • One participant experienced treatment-related rhabdomyolysis.

        Patient & Prescribing Data

        Healthy participants in a clinical trial

        Potential for once- or twice-daily dosing based on pharmacokinetic data.

        Clinical Best Practices

        • Monitor for mild to moderate adverse events during treatment.
        • Consider food effects on drug absorption when prescribing.

        Related Resources & Content

        Original Source(s)

        Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

        • by Andrea Surnit

        • July 6, 2026

        Related Content

        Tenderness Tracks Ultrasound Findings

        Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.

        Sex-based differences in hip replacement outcomes

        A systematic review of more than 2.3 million patients found that women and men had different patterns of postoperative complications and recovery, with age and implant strategy modifying observed differences.

        Serostatus May Modify RA Activity–CV Link

        Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.